The COVID-19 vaccination campaign is being carried out rapidly in India. Vaccine production is in full swing. More than half of the youth population in the country has been given at least one dose of vaccination. In such a situation, given the huge jump in the supply of Kovid 19 vaccine in India, there are hopes that the country will be back as a worldwide exporter in the early months of next year.
After delivering and selling 66 million doses to nearly 100 countries, India halted exports in mid-April to focus on home vaccinations, due to the rapidly spreading infection in India. Was. This affected the vaccination plans of many African and South Asian countries.
India’s daily immunization crossed 1 crore doses on Friday. National vaccine production has more than doubled since April and is set to rise again in the coming weeks. New production lines have been set up, a vaccine developed by Cadila Healthcare (CADI.NS) has recently received approval, and production of Russia’s Sputnik V is starting in India.
Serum Institute of India (SII), the world’s largest vaccine maker, is now producing around 150 million doses of its version of the AstraZeneca (AZNL) shot, up from around 65 million in April. That is, at present this figure of production is more than double after the month of April.
“There is no fixed timeline on exports, but the company expects to restart in a few months,” the source said. Global vaccine sharing platform COVAX expects India to resume overseas sales as soon as possible.
A spokesperson for GAVI, co-head of the platform, told Reuters in an email: “With the successful national immunization and the arrival of more products, we expect Indian supplies to COVAX to resume as soon as possible.”
Bharat Biotech, maker of India’s first domestically developed COVID-19 shot, on Sunday inaugurated a new factory with a production capacity of 10 million doses a month. It said it is moving toward a goal of total annual capacity of about 1 billion doses of the drug Covaxin.